Pfizer and Wyeth began joint operations on Oct. 16.
With the acquisition, Pfizer Animal Health reports that it now offers an enhanced portfolio in beef, dairy and companion animals, as well as a redefined product line for swine, equine and poultry.
Pfizer Animal Health’s new U.S. product portfolio summary includes:
- Beef and diary – Factrel (gonadorelin hydrochloride) and the line of Synovex implants, which the company said complements the current U.S. cattle portfolio, such as Draxxin (tulathromycin), Dectomax, Excede (ceftiofur crystalline free acid), Excenel (cefriofur hydrochloride), Bovi-Shield Gold, Lutalyse (dinoprost tromethamine), Orbeseal and Spectramast (ceftiofur hydrochloride).
- Swine – Suvaxyn brands, including Suvaxyn PCV-2 vaccine for circovirus. The company said this addition rounds out the line of Respisure, Flusure, Draxxin and Excede.
- Poultry – The acquisition adds a broad range of poultry vaccines, including Poulvac and Maternavac IBD-Reo, a broiler-breeder vaccine.
West Nile Innovator, Flu Vac Innovator and Quest (moxidectin) and Quest Plus (moxidectin/praziquantel), additions to Pfizer Animal Health’s Strongid (pyrantel pamoate), Dormosedan (detomidine hydrochloride) and Hylartin (sodium hyaluronate).
The acquisition brings in the vaccine Lymevax, which complements the current Vanguard canine vaccine line, as well as several anesthetic products. These products join current offerings such as Revolution (selamectin), Cerenia (maropitant citrate), Convenia (cefovecin sodium), Rimadyl (carprofen) and Slentrol (dirlotapide).
Pfizer Animal Health also reported that all current U.S. pricing, product distribution, programs and policies for its products, including the acquired Fort Dodge products, will remain in place through the end of the year.
|Related News: Pfizer Closes Wyeth Acquisition Deal|